Drug Farm Announces IND Clearance by U.S. FDA Enabling Phase 1b Initiation for ALPK1 Selective Kinase Inhibitor, DF-003 in ROSAH Syndrome Patients

Drug Farm announced the U.S. Food and Drug Administration has cleared the Investigational New Drug application of DF-003, a first-in-class, oral, potent, highly selective alpha-kinase 1 inhibitor for clinical evaluation in ROSAH syndrome patients.